10 Strong Buy Small Cap Stocks to Invest In
In this article, we will take a look at 10 Strong Buy Small Cap Stocks to Invest In.
Xeris Biopharma Holdings Inc. (XERS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,119,076 | $10,698,367 | +16% | 0% |
| 2. | Dorset Management David M. Knott | 1,002,900 | $9,587,724 | -6% | 5.24% |
| 3. | Royce & Associates Chuck Royce | 588,178 | $5,622,982 | +28% | 0.05% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 293,055 | $2,801,606 | 0% | |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 259,136 | $2,477,340 | -30% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.38 | 25,000 | $109,475.00 | 1,708,585 | 2025-06-13 | Filing | |
| $2.25 | 4,515 | $10,147.01 | 25,200 | 2024-08-12 | Filing | |
| $2.37 | 4,285 | $10,134.03 | 20,685 | 2024-08-09 | Filing | |
| $1.91 | 5,400 | $10,314.00 | 16,400 | 2024-05-10 | Filing | |
| $2.16 | 4,500 | $9,720.00 | 11,000 | 2024-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.49 | 25,000 | $312,215.00 | 1,559,208 | 2026-11-05 | Filing | |
| $10.23 | 5,000 | $51,173.50 | 1,346,053 | 2026-11-02 | Filing | |
| $10.23 | 25,000 | $255,827.50 | 1,086,130 | 2026-11-02 | Filing | |
| $10.23 | 15,000 | $153,487.50 | 1,584,208 | 2026-11-02 | Filing | |
| $9.41 | 5,000 | $47,036.50 | 1,351,053 | 2026-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,574,524 | $53,292,449 | 0% | |
| 2. | 4,570,751 | $43,704,790 | 0% | |
| 3. | 4,141,888 | $39,596,450 | 0.01% | |
| 4. | 2,381,573 | $23,768,099 | 0% | |
| 5. | 1,695,568 | $16,213,597 | 0% |
News See All
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list.
12 Best Low-Priced Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 12 Best Low-Priced Pharma Stocks to Buy Right Now.
Jim Cramer Discussed 15 Stocks, Including Broadcom, Netflix, and His Skepticism Toward Tech Stocks
In this article, we will look at the stocks Jim Cramer commented on, as he explained that tech stocks cannot be trusted to lead anymore.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2026 Earnings Call Transcript May 7, 2026Xeris Biopharma Holdings, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.00274.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript March 2, 2026Xeris Biopharma Holdings, Inc. beats earnings expectations.
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory
We came across a bullish thesis on Xeris Biopharma Holdings, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research and Rudy Does Research.
7 Hidden Multibagger Stocks to Invest In
In this article, we will take a look at the top 7 hidden multibagger stocks to invest in.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2025 Earnings Call Transcript November 6, 2025Xeris Biopharma Holdings, Inc. misses on earnings expectations.
Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue
We recently published 10 Best Biotech Stocks to Buy Under $10. Xeris Biopharma Holdings, Inc. is placed among them. Xeris Biopharma Holdings, Inc.
Hedge Fund Resource Center